Navigation Links
Imaging technology might help doctors determine best treatment for Crohn's disease patients
Date:10/14/2011

ANN ARBOR, Mich. It's difficult for doctors to tell whether a patient with Crohn's disease has intestinal fibrosis, which requires surgery, or inflammation, which can be treated with medicine. A new imaging method might make that task easier, according to a U-M-led study.

Ultrasound elasticity imaging, or UEI, could allow doctors to noninvasively make the distinction between inflammation and fibrosis, allowing patients to receive more appropriate and timely care. The study was published in the September edition of Gastroenterology.

Crohn's disease patients suffer from chronic inflammation of the intestines, which over time can cause scar tissue to form, resulting in intestinal fibrosis.

Patients with intestinal inflammation usually are treated with medicines that suppress their immune system, while patients with fibrosis are treated surgically. Because current diagnostic tests, including CT scans and MRIs, cannot detect the difference between the two conditions, many patients with fibrosis are often initially treated with immune system-suppressing drugs, which are expensive and are unlikely to help.

"These therapies are potent, costly and carry risk," says Ryan Stidham, M.D., clinical lecturer in the Department of Internal Medicine. "And for patients with fibrosis, such treatment might be for naught."

Inflamed intestinal tissue is softer than fibrotic tissue, which is hard and thick. The new method uses ultrasound to measure the relative hardness and thickness of tissue inside the body, potentially allowing doctors to differentiate between the two conditions without performing surgery. In animal models, UEI was able to accurately tell the difference between inflamed tissue and scar tissue.

"The goal of this study is to have technology that can make the distinction between fibrosis and inflammation," says Stidham, the lead author of the study. "We want to know if it's worth it to push medical therapy, or if a person is destined for surgery."

The researchers also found that UEI was capable of differentiating between fibrotic and unaffected intestine in a pilot human study. Patients already scheduled for surgical treatment underwent UEI assessment prior to surgery, and fibrotic strictures were identified in each case.

Stidham says the next step in the group's research is a long-term human clinical trial, beginning this winter. If UEI is able to accurately assess a patient's condition, doctors will be able to more efficiently treat Crohn's disease patients suffering from inflammation or fibrosis.

"UEI has great potential to provide a clear measurement that helps clinicians judge whether medical or surgical management is best for the individual patient earlier in their disease course." Stidham says.


'/>"/>

Contact: Justin Harris
juaha@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Neuroimaging study may pave way for effective Alzheimers treatments
2. SNMs Conjoint Mid-Winter Meetings continue to advance molecular imaging
3. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
4. Less is more in cancer imaging
5. Imaging manufacturers: Plan to reduce unnecessary radiation exposure and medical errors
6. National Council on Aging Releases Survey on Medical Imaging Safety
7. Artists, Product Designers, Printing Gurus, Game Developers, Manufacturing Engineers Will Converge at RAPID 2010/3D IMAGING Conference/Expo, May 18-20 in LA
8. Promega - TOP srl Agreement Enables Live Animal Imaging for Cancer Studies
9. Imaging fat layer around heart can help predict disease
10. ModiFace Launches VuMe in Southern Florida – the World's First Full-Featured Touch-Screen Cosmetic Surgery Imaging System
11. Midroog Ltd., an Affiliate of Moodys Investors Services, Rates Potential new Debt of Elbit Imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Compensation Research Institute (WCRI) officially opened registration today for its 33rd Annual ... in Boston, MA . , The theme of the conference is “Persistent Challenges ...
(Date:12/8/2016)... and JENNERSVILLE, Pa. (PRWEB) , ... December 08, ... ... that Penn Medicine Southern Chester County, a Property owned by an affiliate of ... million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental Laboratories ... and patients about the safety issues related to dental restorations. According to the American ... projected to reach $6.4 billion in 2018 with more than 30 million Americans missing ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software ... and employees that are both engaging and easy to use. Coming off the ... software company revealed today its plans to roll out new AI-powered self-service enhancements ...
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ISLAND, N.Y., ... for adherence to the highest standards of trauma, maternity, cancer and chronic obstructive ... president and CEO, Dr. Daniel Messina. , Among the recognitions, the American College ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Australia Glaucoma Surgery Devices Market Outlook ... "Australia Glaucoma Surgery Devices Market Outlook to 2022", ... Surgery Devices market. The report provides value, in ... average prices (USD) within market segement - Glaucoma ... shares and distribution shares data for each of ...
(Date:12/8/2016)... KEY FINDINGS The global medical lifting sling ... for growth of the medical lifting sling market are ... high recovery cost of injuries and government initiatives to ... refers to an assistive device that helps caregiver transfer ... the lift and hold the patient. It is important ...
(Date:12/8/2016)... 8, 2016  Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...
Breaking Medicine Technology: